WallStSmart

AstraZeneca PLC (AZN)vsBone Biologics Corp (BBLG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.0Profit: 8.5Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.48

BBLG

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 4/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AZNUndervalued (+8.2%)

Margin of Safety

+8.2%

Fair Value

$194.77

Current Price

$185.95

$8.82 discount

UndervaluedFair: $194.77Overvalued

Intrinsic value data unavailable for BBLG.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AZN4 strengths · Avg: 8.8/10
Market CapQuality
$282.69B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
21.9%9/10

Every $100 of equity generates 22 in profit

Operating MarginProfitability
27.9%8/10

Strong operational efficiency at 27.9%

Free Cash FlowQuality
$1.82B8/10

Generating 1.8B in free cash flow

BBLG1 strengths · Avg: 10.0/10
Price/BookValuation
0.4x10/10

Reasonable price relative to book value

Areas to Watch

AZN2 concerns · Avg: 3.0/10
P/E RatioValuation
27.5x4/10

Moderate valuation

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

BBLG4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$2.30M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.

Bull Case : BBLG

The strongest argument for BBLG centers on Price/Book.

Bear Case : AZN

The primary concerns for AZN are P/E Ratio, Altman Z-Score.

Bear Case : BBLG

The primary concerns for BBLG are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

AZN profiles as a mature stock while BBLG is a value play — different risk/reward profiles.

BBLG carries more volatility with a beta of 0.53 — expect wider price swings.

AZN is growing revenue faster at 12.5% — sustainability is the question.

AZN generates stronger free cash flow (1.8B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 26/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Bone Biologics Corp

HEALTHCARE · BIOTECHNOLOGY · USA

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using recombinant human protein. The company is headquartered in Burlington, Massachusetts.

Want to dig deeper into these stocks?